Tissue of Origin® is our microarray-based gene expression test for identification of tissue-of-origin of cancer of unknown primary (“CUP”) and diagnosis of poorly differentiated, undifferentiated or metastatic cancer.
We had acquired all worldwide rights including all the intellectual property rights in and to Tissue of Origin® from Vyant Bio, Inc. (“Vyant”), formerly Cancer Genetics, Inc.
Tissue of Origin® measures gene expression of RNA extracted from FFPE tissue samples and compares expression for 4,975 genes in a patient’s cancer with a panel of 17 cancer categories and 69 cancer subtypes.
It combines genetic testing by sequencing the RNA of FFPE tissue samples with analysis against a proprietary database and algorithm, to provide identification of tissue-of-origin of CUP and diagnosis of metastatic, poorly differentiated and undifferentiated cancer of 17 cancer categories and 69 cancer subtypes.
Tissue of Origin® obtained 510(k) clearance from the FDA in March 2018.